Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): early-phase trial registry
3 of 6 indexed Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): 6 US clinical trials tracked, 3 recruiting.
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Pedro Barata, MD, MSc, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-hormone-sensitive-prostate-cancer-mhspc
OPEN 3 | RECR 50% | LATE 1 | EARLY 5 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) research.
Pedro Barata, MD, MSc accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
University of Utah
NCT07216248
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
NCT07190300
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Amgen
NCT07140900
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Brigham and Women's Hospital
NCT06479187
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
Beth Israel Deaconess Medical Center
NCT05683964
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Pedro Barata, MD, MSc
NCT06312670
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pedro Barata, MD, MSc sponsors the most Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) trials on record, review their full trial history before evaluating a specific study. See Pedro Barata, MD, MSc's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) condition card totals 6 registered trials; most-linked intervention Abiraterone; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.